China Feihe Limited (6186.HK): Analysis of a Market Leader at a Cyclical Trough

Executive Summary & Key Metrics

China Feihe Limited (6186.HK) is the undisputed market leader in China’s Infant Milk Formula (IMF) industry. The company finds itself at a critical inflection point. After delivering solid financial results in FY2024, with revenue growing 6.2% and net profit attributable to owners rising 5.3% , the company reported a severe profit contraction in the first half of FY2025. For the six months ended 30 June 2025, revenue declined 9.4% and profit for the period collapsed 46.0%.

Management attributes this sharp decline to temporary, strategic factors: a deliberate reduction of channel inventory to ensure product freshness and a significant, short-term margin sacrifice to fund “childbirth subsidies” (promotional activities) to capture new customers. The investment thesis hinges on whether 1H 2025 was a “kitchen sink” period designed to reset expectations and set a low base for recovery, or the start of a secular decline.

Supporting the former, the company possesses a formidable “fortress” balance sheet. As of 30 June 2025, China Feihe held a net cash position of approximately RMB 16.83 billion. This represents approximately 48.8% of its current market capitalization, providing a substantial margin of safety and the financial firepower to fund its generous shareholder return policy, even during a period of negative free cash flow.

The stock is currently trading near its 52-week low at its lowest P/E and P/B multiples in five years, suggesting extreme pessimism is priced in. Management’s signal of an approximately 100% dividend payout ratio for the 1H 2025 interim dividend, despite the earnings trough, underscores its confidence in a recovery.

Key Metrics

Company Overview

Background

China Feihe’s operational history traces back to 1962 with its predecessor, Hongguang Dairy. The modern iteration of the company was established in 2001 by its current Chairman and CEO, Mr. Leng Youbin. The company has a complex listing history, including an initial listing on the OTCBB in 2003, a move to the NYSE, and a subsequent privatization in 2013. China Feihe Limited, as it is structured today, was listed on the Main Board of the Hong Kong Stock Exchange (HKEX) on 13 November 2019.

Business Nature

The Group’s principal activity is the production, distribution, and sale of dairy products and nutritional supplements. It operates two primary business segments: 1) Dairy products and nutritional supplements, and 2) Raw milk. The raw milk segment, which includes its subsidiary YuanSheng Tai, functions largely as a captive supplier, providing high-quality fresh milk for its core IMF products and ensuring stringent quality control.

The core business is high-end Infant Milk Formula (IMF) specifically formulated for Chinese infants. The company’s brand value proposition, “More Suitable for Chinese Babies”, has been a highly successful marketing strategy in post-scandal China.

Operations & Geography

Feihe’s operations are overwhelmingly concentrated in Mainland China, which accounted for 98.8% of the Group’s total revenue in the first half of 2025.

The company also operates a small, financially immaterial nutritional supplement business, Vitamin World USA, which it acquired in 2018. This segment operated 42 specialty retail stores in the United States as of 30 June 2025, accounting for just 1.0% of total Group revenue in 1H 2025.

Feihe’s primary competitive advantage lies in its extensive offline distribution network. As of 30 June 2025, it utilized over 2,700 offline customers to cover approximately 70,000 retail points of sale. This network, which is heavily weighted towards difficult-to-replicate maternity stores, remains the dominant sales channel, accounting for 71.9% of total dairy product revenue in 1H 2025.

As of 30 June 2025, the Group had 11 production facilities with a designed annual production capacity exceeding 440,000 tonnes.

Major Products & Services

• Infant Milk Formula: This is the dominant revenue and profit driver. The portfolio is segmented to cater to a wide customer base, primarily through its Super-Premium (e.g., Astrobaby / 星飞帆) and Premium series.
• Other Dairy Products: This includes adult milk powder, liquid milk, rice powder supplements, and other products.
• Nutritional Supplements: This segment consists of the Vitamin World USA business, retailing vitamins, minerals, and herbs.

High Growth Areas

Management has explicitly recognized the demographic risk of a business focused purely on infant nutrition. The declining birth rate in China has necessitated a strategic pivot. The company’s stated “new mission and vision” is to transition from “family health to nutrition for all age groups”. This long-term strategy involves leveraging its powerful brand trust and R&D capabilities to expand into adult nutrition, functional foods (e.g., “AIBEN Enjoy Move Functional Powder”), and other products that serve consumers across their entire life cycle. This pivot is in its nascent stages and represents the key long-term growth opportunity, but also a significant execution risk.

Industry Landscape and Competitive Positioning

Global Industry Overview

The Chinese IMF market is the largest and most significant in the world, with a retail sales value of approximately RMB 129 billion in 2025. The industry is defined by a major structural headwind: a declining birth rate. China’s birth rate fell to 6.77% in 2024, with the number of newborns dropping to approximately 9.5 million. This has caused the core IMF-consuming demographic (children aged 0-3) to shrink from approximately 47.1 million in 2019 to 28.1 million in 2024.

Consequently, market growth is no longer driven by volume. Instead, the key industry driver is premiumization. Chinese parents are spending more money per child, driving demand for “ultra-premium” products with scientifically-backed functional ingredients.

In response to this demographic trend, the PRC government has initiated significant pro-natalist policies. A key catalyst is the new national childcare subsidy program, which provides RMB 3,600 per year for every child under the age of three, effective from 1 January 2025. This policy is expected to support consumption in the sector.

China Feihe is the dominant market leader, having ranked first in the Chinese IMF market for six consecutive years (2019-2024). As of May 2025, its omnichannel market share stood at 18.6%.

Competitive Advantages (Moat)

Feihe’s market leadership is built on several key competitive advantages:

1. Brand & Trust: In a market scarred by the 2008 melamine scandal, trust is the most valuable asset. Feihe’s marketing proposition, “More Suitable for Chinese Babies”, has cultivated a powerful brand identity that resonates with consumer preferences for domestic, high-quality products. This has allowed Feihe to successfully price its domestic products at a premium comparable to foreign brands.
2. Distribution Network: The company’s “in-depth” distribution network of ~70,000 retail points of sale, particularly its entrenchment in specialized maternity stores, serves as a significant barrier to entry for competitors.
3. Vertical Integration & Quality Control: Through its ownership of the raw milk segment (YST), Feihe controls its upstream fresh milk supply. This allows for superior quality control and supports its “freshness” marketing, a key differentiator in the premium segment.

Major Competitors

The Chinese IMF market is a highly competitive oligopoly:

• Domestic Competitors: Yili Group (owner of the JinLingGuan brand and the #1 goat milk brand, Ausnutria / Kabrita) and Mengniu Dairy (owner of Yashili).
• International Competitors: Nestlé, Danone, and Health and Happiness (H&H) (owner of Biostime).

This market is not static; in 2024, international brands like Danone and Nestlé achieved strong growth by innovating in the high-end segment. Feihe must continuously invest in R&D and marketing to defend its market-leading position.

Competitive Strategy

Feihe’s strategy is two-fold:

1. Defend the Core (IMF): Aggressively acquire new customers and defend its #1 share. The “childbirth subsidies” (promotions) mentioned in the 1H 2025 report are a clear execution of this defensive, market-share-oriented strategy.
2. Expand the Total Addressable Market (TAM): Execute the strategic pivot to “nutrition for all age groups” to de-risk the business from the declining birth rate and create new growth vectors.

Specific Market Exposure and Risks

The company’s geographic exposure is almost exclusively concentrated in Mainland China (>98% of revenue).

This concentration creates a unique, and arguably inverse, risk profile. China Feihe faces minimal direct risk from US-China trade tensions, tariffs, or sanctions, as its supply chain and customer base are almost entirely domestic. The company’s minor US asset, Vitamin World (acquired for ~$28 million), is financially immaterial.

Furthermore, the indirect effect of geopolitical tension may be a net positive. Rising nationalism and “Buy China” sentiment reinforce Feihe’s core brand message, while its primary foreign-owned competitors (Nestlé, Danone) face potential supply chain and political headwinds.

The primary external risk is not geopolitical but domestic PRC regulation. The Chinese government, through the State Administration for Market Regulation (SAMR), heavily regulates the IMF industry. This risk is a double-edged sword. New, stricter standards (like the “new GB” standards implemented in February 2023) and tighter registration requirements create significant R&D and compliance costs. However, this process ultimately benefits the market leader. It accelerates market consolidation by forcing smaller, lower-quality, and non-compliant players out of the market. As the #1 player with strong R&D, Feihe is a long-term beneficiary of this stringent regulatory environment.

Management Discussion and Analysis (MD&A) Summary

Business Overview & Trends (FY2024)

Management presented FY2024 as a year of solid achievement, with revenue increasing 6.2% to RMB 20.75 billion and profit for the year rising 11.1% to RMB 3.65 billion. Key highlights included advancements in R&D (deepening the “Brain Development” strategy) and technological innovation. The core forward-looking strategy was the stated pivot from “family health to nutrition for all age groups”.

Segment/Regional Performance (1H 2025)

The 1H 2025 report provided a starkly different picture, explaining the 46.0% collapse in net profit.

• Revenue Decline (-9.4%): Management explicitly attributed this to two factors: 1) A strategic reduction in channel inventory to “maintain the freshness and quality of products,” and 2) The company “providing childbirth subsidies to consumers”.
• Gross Margin Decline (67.9% to 61.6%): This compression was attributed to a “increased in contribution of the sales of raw material powders,” which carry a lower margin than branded IMF products.
• Profit Decline (-46.0%): This was a result of the above, compounded by a 37.4% decrease in “Other income and gains, net” (due to lower government grants) and a 25.7% increase in impairment losses on biological assets.

Management Strategy & Future Prospects

The 1H 2025 results appear to be a classic “kitchen sink” or “reset” quarter, designed to flush out all negative items simultaneously to set a low base for a future recovery.

1. “Channel Destocking” : This is a non-recurring event. The company is forcing its distributors to sell down existing inventory. This means Feihe’s reported revenue (sales to distributors) is temporarily lower than the actual end-consumer sales (sales by distributors). Management has indicated it expects this adjustment to be completed by the third quarter of 2025. This points to a normalization of revenue in 2H 2025 and FY2026.
2. “Childbirth Subsidies”: This term refers to Feihe’s own aggressive promotional spending, not the government’s program. This is a deliberate, front-loaded margin sacrifice—a Customer Acquisition Cost (CAC)—timed to acquire the new cohort of mothers supported by the new national subsidies.
3. “Impairment” : The impairment on milk powder and biological assets is a non-cash charge.

The 1H 2025 results are therefore deliberately suppressed and mask a likely more stable underlying consumer demand. Management is aggressively cleaning the sales channel and investing heavily in promotions to defend its #1 market share.

Financial Performance Analysis

Income Statement Review

• FY2024 (vs. FY2023):
  • Revenue: Increased 6.2% to RMB 20.75 billion.
  • Gross Profit: Increased 8.7% to RMB 13.76 billion.
  • Gross Margin: Expanded to 66.3% from 64.8% in FY2023.
  • Net Profit (Attributable to Owners): Increased 5.3% to RMB 3.57 billion.
  • Basic EPS: RMB 0.39.
  • S&D Expenses: RMB 7.18 billion (34.6% of revenue).
  • Admin Expenses: RMB 1.68 billion (8.1% of revenue).
  • R&D Expenses: Approximately RMB 585 million (2.8% of revenue).
• 1H 2025 (vs. 1H 2024):
  • Revenue: Decreased 9.4% to RMB 9.15 billion.
  • Gross Profit: Decreased 17.8% to RMB 5.63 billion.
  • Gross Margin: Contracted sharply to 61.6% from 67.9%.
  • Profit for the Period: Collapsed 46.0% to RMB 1.03 billion.
  • Basic EPS: Fell to RMB 0.11 from RMB 0.21.
  • S&D Expenses: Decreased 10.2% to RMB 3.17 billion, demonstrating strong cost control despite the “subsidy” campaign (which likely manifests as a revenue reduction or COGS, not S&D).
  • Admin Expenses: Increased 4.7% to RMB 773.7 million.

Balance Sheet Review

China Feihe’s primary strength is its fortress balance sheet. As of 30 June 2025:

• Net Cash Position:
  • Cash and cash equivalents: RMB 6.48 billion
  • Structured deposits (liquid, cash-like): RMB 10.39 billion
  • Long-term bank deposits & Restricted cash: RMB 0.74 billion
  • Total Cash & Equivalents: RMB 17.61 billion
  • Total Interest-bearing bank borrowings (Current + Non-Current): RMB 0.78 billion
  • Net Cash Position: RMB 16.83 billion
• Liquidity:
  • Total Current Assets: RMB 20.43 billion
  • Total Current Liabilities: RMB 5.31 billion
  • Current Ratio: 3.85x (Extremely strong)
  • Quick Ratio: (Current Assets – Inventory) / Current Liabilities = (20.43B – 2.05B) / 5.31B = 3.46x (Extremely strong)
• Financial Strength & Leverage:
  • The company is virtually unlevered.
  • Debt-to-Equity: (RMB 0.78B Debt / RMB 27.15B Equity) = 2.88%
  • Gearing Ratio (Net Debt / Total Capital): (0.22), indicating a high net cash position.

Cash Flow Review

• FY2024: The company demonstrated robust cash generation.
  • Cash Flow from Operations (OCF): RMB 4.18 billion.
  • Capital Expenditure: RMB 1.40 billion.
  • Free Cash Flow (FCF): RMB 2.78 billion.
• 1H 2025: OCF collapsed in line with the “kitchen sink” narrative.
  • Cash Flow from Operations (OCF): RMB 77.4 million (down from RMB 1.57 billion in 1H 2024).
  • This collapse, despite a net income of RMB 1.03 billion, was driven by large negative swings in working capital, including an increase in receivables (RMB 517M), a decrease in trade payables (RMB 129M), and a decrease in other payables (RMB 749M).
  • This cash flow data strongly corroborates management’s claims of a channel reset (impacting receivables) and significant cash outlays for promotions (impacting payables). It confirms the 1H 2025 event was a temporary but significant cash event, not just a non-cash P&L charge.

Dividend Analysis and Sustainability

The company’s stated dividend policy is to distribute no less than 30% of net profit for each financial year. In practice, its payout has been far higher.

Historical Payout

The following table details dividends paid per share in HK$:

Payout Ratios (FY2024)

• FY2024 EPS: RMB 0.39
• FY2024 DPS (Declared): HK$ 0.3264
• Converted DPS (RMB): ~RMB 0.356 (using 1.09 RMB/HK$ avg.)
• FY2024 Payout Ratio (Earnings): (0.356 / 0.39) = 91.3%
• FY2024 Payout Ratio (FCF): (Dividends Paid RMB 2.6B / FCF RMB 2.78B) = 93.5%

Sustainability of Dividend and Estimate of Forward Dividend

The FY2024 dividend was barely covered by FCF (1.07x coverage). The 1H 2025 FCF was negative. This confirms the dividend is not currently covered by operational cash flow.

However, management sent a powerful signal in 1H 2025. They declared an interim dividend of HK$ 0.1209. The company explicitly stated this represents “approximately 100% of our profit for the six months ended 30 June 2025”.

This action demonstrates an extreme commitment to the dividend and powerful confidence in a 2H 2025 earnings recovery. Management is using the balance sheet to bridge the dividend through the trough.

D1 (FY2025) Estimate: The most conservative assumption is that management repeats the interim dividend for the final dividend.

• D1 ( = HK$ 0.1209 (Interim) + HK$ 0.1209 (Final) = HK$ 0.2418
• This implies a Forward Dividend Yield of 5.83% (at 4.15 HK$).

This estimated dividend is not fully covered by consensus FY2025 earnings (implying a 75-80% payout) and is not covered by 1H 2025 FCF. However, it is massively covered by the RMB 16.83 billion net cash pile. The dividend is sustainable from the balance sheet in the short-term, giving management 1-2 years for earnings and FCF to recover.

Coverage Ratios (FY2024)

Valuation Assessment

Fundamental Assessment

China Feihe is a wide-moat market leader with a fortress balance sheet, currently experiencing a severe but likely temporary cyclical trough. The stock is priced for a worst-case scenario, creating a margin of safety.

Dividend Discount Model (DDM)

Using the Gordon Growth Model (P0 = D1 / (ke – g)) to value the dividend stream:

• D1 (Est. FY2025 Dividend): HK$ 0.2418
• ke (Cost of Equity): 9.0%
  • Risk-Free Rate (Rf): 3.0% (HK 10-yr Gov’t Bond Yield)
  • Equity Risk Premium (ERP): 6.0% (Standard for HK/China)
• g (Perpetual Growth Rate): 2.5% (Conservative Assumption)
  • Sustainable Growth Rate (ROE x (1-POR) = ROE (14.03% ) x Retention Ratio (1 – Est. Payout 76%) = 3.37%
• Intrinsic Value P0: HK$ 0.2418 / (9.0% – 2.5%) = HK$ 3.72

Relative Valuation

Feihe is trading at 5-year lows on both P/E and P/B multiples. Its TTM P/E of 12.9x and Forward P/E of 11.75x are at the low end of its peer group, despite its #1 market share and superior balance sheet.

Sum-of-the-Parts (SOTP) / “Stub” Valuation

While a full SOTP is not relevant, an “Ex-Cash” or “Stub” valuation is highly insightful.

1. Market Capitalization: HK$ 37.55 Billion
2. Net Cash (30 June 2025): RMB 16.83 Billion = HK$ 18.34 Billion
3. Implied “Stub” Value of Operating Business: HK$ 37.55B – HK$ 18.34B = HK$ 19.21 Billion
4. Consensus FY2025E Net Income: RMB 2.63 Billion (based on RMB 0.29 EPS) = HK$ 2.87 Billion
5. Implied Stub P/E: HK$ 19.21B / HK$ 2.87B = 6.7x

The market is valuing the #1 IMF brand in China, with an 18.6% market share , at just 6.7x trough earnings. This is an exceptionally low multiple for a wide-moat consumer staple.

Investment Outlook: Catalysts and Returns

Potential Catalysts (12-18 months)

1. Completion of Channel Destocking: Management guided for completion by Q3 2025, which should lead to a normalization of revenue and OCF in 2H 2025 and FY2026.
2. Earnings Recovery: Analyst consensus forecasts a strong EPS rebound of 14.6%-14.9% p.a. from the low 2025 base.
3. Impact of National Subsidies: The new national childcare subsidy may increase the total spend per child, benefiting premium players like Feihe.
4. Share Buybacks: The massive net cash position could be deployed for a large-scale, EPS-accretive buyback program.
5. Analyst Upgrades: Any sign of a 2H 2025 recovery would likely reverse the recent downgrades.

Long-Term Return Expectation (5-Year Horizon)

A conservative 5-year annualized total return estimate can be projected:

• 1. Dividend Yield: 5.83% (Based on D1 estimate of HK$ 0.2418).
• 2. Sustainable Growth: 3.5% – 4.0% p.a. (Based on sustainable growth rate estimate and long-term nominal GDP growth expectations).
• 3. Multiple Re-rating: A partial re-rating of the P/E multiple from its trough (11.8x Fwd) toward its peer average (~14x) could add 3-4% p.a.

Estimated 5-Year Annualized Total Return: 5.83% (Yield) + 3.5% (Growth) + 3.5% (Re-rating) = ~12.83% p.a. This represents a highly attractive potential return for a low-risk, market-leading staple.

Risk Assessment

Key Risks

1. Demographic Risk (Structural): The primary, unavoidable risk is China’s declining birth rate, which structurally shrinks the company’s core IMF market.
2. Competitive Risk (Intense): The IMF market is a “zero-sum game”. Feihe must constantly spend on S&D (like the 1H 2025 “subsidies”) to defend its #1 share from powerful domestic (Yili, Mengniu) and international (Nestlé, Danone) rivals.
3. Margin Compression Risk: The 1H 2025 promotional spending may not be temporary. Intense competition could make high S&D spending a permanent feature, structurally lowering long-term profit margins.
4. Execution Risk: The strategic pivot to “nutrition for all age groups” is critical for long-term growth but is unproven and outside the company’s core expertise.
5. Food Safety Risk: As a premium food producer, a single product quality or safety scandal would be catastrophic for the brand, which is built entirely on trust.

Downside Catalysts

• A 2H 2025 earnings report that misses expectations, proving the destocking was not the only headwind.
• A cut to the final dividend, signaling a lack of management confidence in the recovery.
• A major food safety scandal involving the company or the broader industry.

Downside Scenario Estimate

The stock has a hard, quantifiable floor. In a severe downside scenario, the company’s value reverts to its tangible net cash.

• Net Cash (30 June 2025): HK$ 18.34 Billion (from Section 8)
• Shares Outstanding: 9.067 Billion
• “Rock Bottom” Cash-per-Share Value: HK$ 2.02 per share

The current price of HK$ 4.15 is significantly above this cash floor, but this floor is much higher than for any of its peers and provides an exceptional margin of safety. The 52-week low of HK$ 3.80 acted as a strong support level well above this cash-only value.

Conclusion

The market has over-reacted to the 1H 2025 “kitchen sink” quarter, pricing the stock for a permanent impairment. The channel destocking and heavy promotional costs can be viewed as temporary, strategic investments to solidify market leadership. The current valuation of HK$ 4.15 is highly compelling, as it trades at 5-year low multiples and implies the market-leading operating business is valued at only ~6.7x trough earnings (ex-cash).

For the value dividend investor, the estimated forward yield of 5.83% is attractive. While this dividend was cut from FY2024 levels and is not currently covered by free cash flow, its sustainability is exceptionally high. The dividend is backstopped by a net cash position (RMB 16.83B) that could fund the entire dividend for years without any earnings. The 100% 1H 2025 payout is also a powerful signal of management’s confidence in future earnings recovery.

Disclaimer

This article is a record of the thinking behind a personal investment decision. It does not represent any recommendation to purchase any stock mentioned in the article. As always, readers are strongly advised to do their own due diligence before making any investment decisions.